| Year | Presented | TITLE | Authors |
|---|---|---|---|
| 2018 | EASL | Direct Acting Antiviral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Real World Experience from the HCV-TARGET Cohort | Verna EC, Morelli G, Terrault N, Lok AS, Lim J, Di Bisceglie AM, Zeuzem S, Landis C, Lutchman G, Hassan M, Manns M, Vainorius M, Akushevich L, Nelson D, Fried M, Reddy KR |
| 2017 | EASL | Incidence of and predictors for direct acting antiviral treatment failure among 4099 hepatitis C genotype 1 infected adults: Real world outcomes from HCV TARGET | Sulkowski, MS; Reddy, R; Nelson, DR, Lim, JK; Galati, JS; Kuo, A; Terrault, N; Lok, AS; Pearlman, BL; Vainorius, M; Akushevich, L; Fried, MW; Di Bisceglie, AM |
| 2017 | EASL | Safety and Efficacy of Sofosbuvir and Velpatasvir with or without Ribavirin for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study | Khalili, M; Welzel, TM; Terrault, N; Lim, J; Sridhar, A; Lutchman, G; Nelson, D; Borg, B; Lok AS; Ramani, A; Reau, N; Vainorius, M; Fried, MW; Landis, C |
| 2017 | EASL | Safety and Efficacy of Elbasvir and Grazoprevir with or without Ribavirin for the Treatment of HCV Genotype 1: Results of the HCV-TARGET Study | Pearlman, BL; Lutchman, G; Shiffman, ML; Patel, J; Frazier, LM; Galati, JS; Gallant, JE; Ramani, A; Vainorius, M; Nelson, DR; Fried, MW; Dong, M; Khalili, M; Ben-Ari, Z |
| 2016 | AASLD | Safety and Tolerability of Direct Acting Antiviral Agents (DAAs) Used in Usual Clinical Practice: HCV-TARGET International Consortium | Michael W. Fried, K. Rajender Reddy, Mitchell L. Shiffman, Stefan Zeuzem, Norah Terrault, Alexander Kuo, Paul J. Pockros, Mark S. Sulkowski, Michael P. Manns, Jacqueline G. O'Leary, Lucy Akushevich, Monika Vainorius, David R. Nelson, Joseph K. Lim |
| 2016 | APASL | SAFETY AND EFFICACY OF ORAL REGIMENS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1b INFECTION: HCV-TARGET INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY | Manns M, Nelson DR, Zeuzem S , Di Bisceglie AM, Ben-Ari, Z, Lok AS, Pockros P, Lim JK, Kuo A, Reddy R, Frazier L, Stewart P, Vainorius M, Sulkowski MS, Fried MW |
| 2016 | EASL-AASLD Spec Conf Sept2016 | SAFETY AND EFFECTIVENESS OF 12 AND 24-WEEK REGIMENS OF LEDIPASVIR/SOFOSBUVIR (LDV/SOF) IN TREATMENT EXPERIENCED GENOTYPE 1 CIRRHOSIS: INTERIM ANALYSIS HCV-TARGET, A PROSPECTIVE, OBSERVATIONAL STUDY | ML Shiffman , JK Lim, AS Lok , S Zeuzem, N Terrault, JS Park, CS Landis, M Hassan, JE Gallant, AA. Kuo, PJ Pockros, M Vainorius, L Akushevich, MW Fried, DR Nelson, Z Ben-Ari |
| 2016 | EASL-AASLD Spec Conf Sept2016 | SAFETY AND EFFECTIVENESS OF 12 AND 24-WEEK REGIMENS OF PARITAPREVIR/R, OMBITASVIR, DASABUVIR (PrOD) FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1A INFECTION: INTERIM ANALYSIS HCV-TARGET, A PROSPECTIVE, OBSERVATIONAL STUDY | ML Shiffman , JK Lim, AS Lok , S Zeuzem, N Terrault, JS Park, CS Landis, M Hassan, JE Gallant, AA. Kuo, PJ Pockros, M Vainorius, L Akushevich, MW Fried, DR Nelson, Z Ben-Ari |
| 2016 | EASL | Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis | Gary P. Wang, Jackie Reeves, Norah Terrault, Joseph Lim, Giuseppe Morelli, Alexander Kuo, Josh Levitsky, Kenneth Sherman, Lynn M. Frazier, Ananthakrishnan Ramani, Joy Peter, Lucy Akuskevich, Michael W. Fried, David R. Nelson |
| 2016 | EASL | Safety and Efficacy of New DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Interval Results from the HCV-TARGET Study | Reddy KR, Sulkowski MS, Hassan M, Levitsky J, O’Leary JG, Brown RS, Kuo A, Stravitz T, Lim JK, Verna E, Saxena V, Nelson DR, Hayashi P, Vainorius M, Fried MW, Terrault N |
| 2015 | AASLD | SAFETY AND EFFICACY OF SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF HCV GENOTYPE 2 AND 3: RESULTS OF THE HCV-TARGET STUDY | Welzel TM, Nelson DR, Morelli G, Di Bisceglie AM, Reddy KR, Kuo A, Lim JK, Darling JM, Pockros PJ, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Fried MW, Zeuzem S |
| 2015 | AASLD | Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study | N Terrault, S Zeuzem, AM Di Bisceglie, JK Lim, PJ Pockros, LM Frazier, A Kuo, AS Lok, ML Shiffman, Z Ben Ari, T Stewart, MS Sulkowski, MW Fried, and DR Nelson |
| 2015 | ATC | Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results form the HCV TARGET Multicenter Prospective Observational Study | J.G. O'Leary, R.S. Brown, K.R. Reddy, A. Kuo, G. Morelli, R.T. Stravitz, G.T. Everson, C.M. Durand, H.E. Vargas, P. Kwo, C.T. FreneQe, J.A. Peter, M. Vainorius, L. Akushevich, D.R. Nelson, M.W. Fried, N. Terrault |
| 2015 | EASL | All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Report from HCV-TARGET | K. Rajender Reddy, Joseph K. Lim, Alexander Kuo, Adrian M. Di Bisceglie, Hugo E. Vargas, Joseph S. Gala8, Giuseppe Morelli, Gregory T. Everson, Paul Kwo, Robert S. Brown, Mark S. Sulkowski, Lucy Akushevich, Thomas G. Stewart, Monika Vainorius, Joy A. Peter, David Nelson, Michael W. Fried, Michael P. Manns |
| 2015 | EASL | Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal Function: Real-World Experience from HCV-TARGET | V Saxena, FM Koraishy, M Sise, JK Lim, RT Chung, A Liapakis, DR Nelson, M Schmidt, MW Fried, N Terrault |
| 2015 | EASL | SAFETY AND EFFECTIVENESS OF SOFOSBUVIR-BASED REGIMENS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 3 & 4 INFECTIONS: INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY | Alqahtani S, Zeuzem S, Manns MP, Kuo A, Di Bisceglie AM, Reddy R, Mailliard M, O’Leary J, Pockros P, Kwo PY, Lim JK, Vargas HE, Fried MW, Nelson DR, Sulkowski MS |
| 2015 | HEPDART | HCV Therapies in Clinical Practice: HCV-TARGET Studies | Michael W. Fried, M.D., FAASLD |
| 2015 | HCV-TARGET International Registry Do Phase III Trials Translate into Real World | David R Nelson, MD | |
| 2014 | AASLD | Safety and Efficacy of Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Patients with Genotype 1: Interim Results of a Prospective, Observational Study | Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo, A, Reddy KR, Lim JK, Morelli G, Feld JJ, Brown RS, Frazier LM, Fried MW, Nelson DR, Jacobson IM |
| 2014 | Safety and Efficacy of New DAA‐based Therapy for Hepatitis C Post‐Transplant: Interval Results from the HCV‐TARGET Longitudinal, Observational Study | Brown, Jr. RS, Reddy KR, O'Leary JG, Kuo A, Morelli G, Stravitz RT, Durand C, Di Bisceglie AM, Vargas HE, Kwo P, FreneGe CT, Vainorius M, Akushevich L, Fried MW, Terrault N | |
| 2014 | Safety and Efficacy of Sofosbuvir‐Containing Regimens for Hepatitis C: Real‐World Experience in a Diverse, Longitudinal Observational Cohort | Jensen DM, O’Leary J, Pockros P, Sherman K, Kwo P, Mailliard M, Kowdley K, Muir A, Dickson R, Ramani A, Manns M, Lok A, Akushevich L, Nelson D and Fried M | |
| 2013 | AASLD | Safety and Efficacy of Telaprevir (TPV) or Boceprevir (BOC) in Patients with Cirrhosis: Interim Results of a Longitudinal, Observational Study | Afdahl NH, Reau N, Everson GT, Morelli G, Lok AS, Sherman KE, Dickson RC, Regenstein F, Mena EA, Stewart TG, Fried MW, Pockros P |
| 2013 | AASLD | The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from HCV-TARGET Longitudinal Observational Study | Gordon SC, Muir AJ, Lim JK, Pearlman BL, Argo CK, Neff GW, Ramani A, Maliakkal B, Rodriguez-Torres M, Stewart TG, Fried MW, Reddy KR |
| 2013 | EASL | HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR | M.W. Fried, K.R. Reddy, A.M. Di Bisceglie, D.M. Jensen, I.M. Jacobson, M.S. Sulkowski, N.A. Terrault, N.H. Afdhal, S.C. Gordon, P.J. Pockros, P.Y. Kwo, G.T. Everson, K.E. Sherman, A.J. Muir, B.L. Pearlman, T.G. Stewart, M. Vainorius, J.A. Peter, D.R. Nelson |
| 2013 | HEPDART | HCV Treatment Selection and Duration Decision-Making: Real-World Issues with HCV RNA and HCV Genotype Assays Used in Clinical Practice | MW Fried, M Vainorius, KR Reddy, AM Di Bisceglie, DM Jensen, IM Jacobson, M Sulkowski, N Terrault, K Bergquist, TG Stewart, JA Peter, and DR Nelson |
| 2013 | Impact of Age on Safety and Treatment Response in Patients with Hepatitis C (HCV) Treated with Boceprevir or Telaprevir | A. Aronsohn, T Stainbrook, S Mohanty, A Mubarak, J Spivey, P Prashant, T Stewart, MW Fried, I Jacobson | |
| 2013 | Pre-treatment Education and Treatment Completion in Patients with Hepatitis C (HCV) Treated with Boceprevir (BOC) or Telaprevir (TVR) | Mercier DA, Appolo BA, Cardona D, Stewart TG, Vainorius M, Scherschel A, Horne P, Hubbard SB, Keller AL, Richards L, Peter J |
|
| 2013 | Virological Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir or Telaprevir in the U.S. (HCV-TARGET) | AM Di Bisceglie, A Kuo, VK Rustgi, MS Sulkowski, TG Stewart, JM Fenkel, H ElGenaidi, M Mah’moud, GM Abraham, MW Fried, RK Sterling |
Recent Comments